Form 4: DURECT CFO Disposes Shares in Bausch Health Merger

DURECT Corporation's Chief Financial Officer, Timothy M. Papp, reported the disposition of all beneficial ownership in common stock and cancellation of stock options following the company's acquisition by Bausch Health Americas, Inc.

Summary

• DURECT Corporation was acquired by Bausch Health Americas, Inc. through a tender offer and subsequent merger, effective September 11, 2025.
• Timothy M. Papp, CFO, disposed of 385,000 shares of common stock and an additional 46,659 shares resulting from the settlement of restricted stock units.
• Tendering stockholders received $1.75 per share in cash plus one non-tradeable contingent value right (CVR) per share.
• CVRs entitle holders to a pro rata share of two milestone payments up to $350,000,000 in aggregate, contingent on the achievement of specified milestones.
• Stock options with an exercise price equal to or greater than the $1.75 cash amount were canceled, and holders are eligible for cash retention bonuses tied to net sales milestones.
• Papp's stock options with exercise prices of $4.515 and $5.07 were among those canceled.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, which provides immediate cash value to shareholders and potential future upside via CVRs. While the company ceases to exist independently, the transaction itself is a positive outcome for the acquired entity's shareholders and management, albeit with some options being canceled.

Positives

• Shareholders received a cash consideration of $1.75 per share, providing immediate liquidity.
• Shareholders also received contingent value rights (CVRs) offering potential future payments up to $350,000,000 based on milestone achievements.
• Certain option holders are eligible for cash retention bonuses tied to net sales milestones, providing an incentive for continued performance post-acquisition.

Negatives

• DURECT Corporation ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Bausch Health Americas, Inc.
• Stock options with exercise prices at or above the $1.75 cash consideration were canceled, potentially resulting in a loss of intrinsic value for some option holders if their options were out-of-the-money relative to the cash consideration.

Risks

• Contingent Value Rights (CVRs) are non-tradeable, and their value is entirely dependent on the achievement of specified future milestones, which may not occur.
• Cash retention bonuses for option holders are subject to the achievement of certain net sales milestones, introducing uncertainty regarding their payout.

Future Outlook

The future outlook for former DURECT shareholders includes potential additional cash payments from non-tradeable Contingent Value Rights (CVRs) if specified milestones are achieved, up to an aggregate of $350,000,000. For certain former option holders, future cash retention bonuses are contingent on the achievement of specific net sales milestones.

Industry Context

This acquisition signifies consolidation within the pharmaceutical or biotechnology sector, where larger entities like Bausch Health acquire smaller companies like DURECT, often for their pipeline assets, technology, or market position. Such mergers are common strategies for growth and portfolio expansion, allowing the acquirer to integrate new capabilities or products.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in M&A transactions is a common mechanism, particularly in the biotech and pharmaceutical industries, to bridge valuation gaps and share future upside potential tied to clinical or commercial milestones. For example, Sanofi's acquisition of Principia Biopharma included CVRs tied to the approval of tolebrutinib.
• The structure of accelerating in-the-money options and canceling out-of-the-money options, while providing retention bonuses for the latter, is a standard practice in M&A to manage employee incentives and ensure continuity post-acquisition.
• The $1.75 cash consideration per share, alongside CVRs, would need to be compared to DURECT's pre-announcement share price and analyst price targets to assess its premium relative to similar transactions in the sector. Without that data, a specific comparison is difficult, but the overall transaction structure is consistent with industry norms for acquisitions.

Corporate Governance

Stakeholder Impact

• Shareholders: Received $1.75 cash per share and non-tradeable Contingent Value Rights (CVRs) for potential future payments, but no longer hold shares in a publicly traded company.
• Employees (specifically option holders): Those with in-the-money options saw accelerated vesting; those with out-of-the-money options had them canceled but are eligible for cash retention bonuses tied to future performance.
• Company (DURECT): Ceased to be an independent public entity, now operating as a wholly-owned subsidiary of Bausch Health Americas, Inc.

Next Steps

• Achievement of specified milestones for Contingent Value Rights (CVRs) to trigger additional payments to former shareholders.
• Achievement of certain net sales milestones for former option holders to receive cash retention bonuses.

Key Dates

Keywords

DURECT, DRRX, Bausch Health, Merger, Acquisition, Tender Offer, Contingent Value Right, CVR, Stock Option, SEC Form 4, Insider Transaction, Timothy Papp, Chief Financial Officer, Corporate Governance, Pharmaceutical, Biotechnology